Patent Application
20230022970
The present invention generally relates to the treatment of enteric neuropathies such as Hirschsprung disease (HSCR) and intestinal hypoganglionosis.
The enteric nervous system (ENS) extends along the entire gastrointestinal tract to control bowel motility, blood flow and epithelial activity in response to sensory stimuli (1). Interconnected enteric ganglia containing neurons and glia develop from neural crest-derived progenitors that migrate through the intestine during prenatal development. Incomplete colonization of distal colon by ENS progenitors causes Hirschsprung disease (HSCR), a condition affecting 1 in 5000 newborns (2,3). In HSCR, distal colon without neural ganglia (i.e., aganglionic colon) remains tonically contracted and does not propagate contractions, causing functional intestinal obstruction. HSCR symptoms include refractory constipation with retention of stool and air, abdominal distension, growth failure, occasional vomiting, bowel inflammation (enterocolitis) and a risk of bacterial translocation into blood causing sepsis and premature death (2).
HSCR is clinically subdivided into short-segment (S-HSCR) and long-segment forms (L-HSCR) (4). S-HSCR, which occurs in >80% of cases, means the ENS is absent from rectum and sigmoid colon. L-HSCR means longer regions of distal bowel are aganglionic. HSCR etiology remains incompletely understood, but many genes influence HSCR risk (2). Furthermore, genetic risk variants may combine with non-genetic factors to prevent full bowel colonization by ENS progenitors (5). This non-Mendelian inheritance occurs because many proteins must work together for normal ENS development.
Since 1948, most children with HSCR have had their life saved by surgical removal of distal aganglionic bowel (16, 17). However, this procedure is far from ideal. Post-surgical complications are common and can also be long-lasting, impacting survival (e.g. enterocolitis) and/or quality of life (e.g., fecal incontinence or obstructive symptoms) (18-20). One promising approach would be “regenerative medicine” to rebuild the ENS and reduce the need for surgery. This idea prompted many groups to develop cell transplantation-based HSCR therapies (21). However, despite many encouraging results, some difficulties remain (22). The optimal source of stem cells, ideal amplification and/or differentiation strategies prior to transplantation, methods of cell delivery, and cell function and fate after transplantation are not yet well defined. Additionally, non-autonomous cell transplantation may require immunosuppression.
Hypoganglionosis, also known as intestinal hypoganglionosis, is a disorder causing a reduced number of nerves in the intestinal wall. Intestinal hypoganglionosis can mimic HSCR; patients with both conditions may present with chronic constipation, intestinal obstruction, and enterocolitis (inflammation of the intestines). Patients with hypoganglionosis may also suffer from severe complications including fecaloma (hardening of the feces inside the colon), bleeding or perforation of the intestine, and breathing problems resulting from a distended colon. The exact cause of hypoganglionosis is often not known. In some cases, it is due to factors present at birth (congenital), while other times it is believed to be an acquired condition. The management of isolated hypoganglionosis generally involves surgery to remove the affected bowel segment.
There is thus clearly a need for alternative treatments for enteric neuropathies such as HSCR and intestinal hypoganglionosis, notably treatments aimed at inducing neurogenesis in the distal colon and restoring distal colon motility in HSCR and intestinal hypoganglionosis patients.
The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.
The present disclosure relates to the use of GDNF for the treatment of one or more pathological features of enteric neuropathies such as Hirschsprung disease.
In aspects and embodiment, the present disclosure relates to the following items 1 to 90:
1. A method for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy, the method comprising administrating a pharmaceutical composition comprising an effective dose of a recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
2. The method of item 1, wherein the GDNF polypeptide comprises an amino acid sequence having at least 70% identity with amino acids 78-211 of SEQ ID NO:1.
3. The method of item 2, wherein the GDNF polypeptide comprises an amino acid sequence having at least 90% identity with amino acids 78-211 of SEQ ID NO:1.
4. The method of item 3, wherein the GDNF polypeptide comprises an amino acid sequence having at least 95% identity with amino acids 78-211 of SEQ ID NO:1.
5. The method of item 4, wherein the GDNF polypeptide comprises amino acids 78-211 of SEQ ID NO:1.
6. The method of any one of items 1 to 5, wherein the effective dose of recombinant GDNF polypeptide administered to the human subject corresponds to a dose of about 5 μg to about 20 μg in a mouse pup.
7. The method of any one of items 1 to 6, wherein the pharmaceutically acceptable carrier comprises a saline solution or a gelling agent.
8. The method of any one of items 1 to 7, wherein the pharmaceutical composition is administered rectally through enema.
9. The method of any one of items 1 to 7, wherein the pharmaceutical composition is administered by injection into the distal colon wall.
10. The method of any one of items 1 to 9, wherein the pharmaceutical composition is administered once-a-day up to four times a day.
11. The method of any one of items 1 to 10, wherein the pharmaceutical composition is administered for at least 2 consecutive days.
12. The method of any one of items 1 to 11, wherein the method is performed prior to surgical removal of the aganglionic or hypoganglionic segment in the subject.
13. The method of any one of items 1 to 11, wherein the method is performed after surgical removal of the aganglionic or hypoganglionic segment in the subject.
14. The method of item 12 or 13, wherein the surgical removal of the aganglionic or hypoganglionic segment is through pull-through surgery.
15. The method of any one of items 1 to 14, wherein the enteric neuropathy is intestinal hypoganglionosis.
16. The method of any one of items 1 to 14, wherein the enteric neuropathy is Hirschsprung disease (HSCR).
17. The method of item 16, wherein the subject suffers from short-segment HSCR.
18. The method of item 16 or 17, wherein the HSCR is sporadic HSCR.
19. The method of any one of items 16 to 18, wherein the HSCR is associated with a reduced expression or activity of the RET receptor.
20. The method of item 19, wherein the HSCR is associated with a mutation in the RET gene.
21. The method of any one of items 1 to 20, wherein the enteric neurogenesis comprises production of enteric neurons and/or enteric glial cells.
22. The method of item 21, wherein the neurogenesis comprises production of enteric neurons and enteric glial cells.
23. The method of item 21 or 22, wherein the production of enteric neurons and/or enteric glial cells comprises proliferation of enteric neurons and/or enteric glia progenitors.
24. The method of any one of items 1 to 23, wherein the method corrects the imbalance of nitrergic and cholinergic neuron subtypes located upstream of the aganglionic or hypoganglionic segment.
25. The method of any one of items 1 to 24, wherein the method restores distal colon motility in the subject.
26. The method of any one of items 1 to 25, wherein the method restores the proportions of lymphoid and/or myeloid immune cells in the distal colon of the subject.
27. The method of any one of items 1 to 26, wherein the human subject is less than 5 years-old, or less than 1-year-old.
28. The method of item 27, wherein the human subject is less than 6-month-old.
29. The method of any one of items 1 to 28, wherein the pharmaceutical composition is administered into the rectum and/or the sigmoid colon.
30. The method of item 29, wherein the pharmaceutical composition is administered or is for administration into the rectosigmoid region.
31. A pharmaceutical composition comprising a recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy, wherein the composition is for administration into the distal colon of the subject.
32. The pharmaceutical composition for use according to item 31, wherein the GDNF polypeptide comprises an amino acid sequence having at least 70% identity with amino acids 78-211 of SEQ ID NO:1.
33. The pharmaceutical composition for use according to item 32, wherein the GDNF polypeptide comprises an amino acid sequence having at least 90% identity with amino acids 78-211 of SEQ ID NO:1.
34. The pharmaceutical composition for use according to item 33, wherein the GDNF polypeptide comprises an amino acid sequence having at least 95% identity with amino acids 78-211 of SEQ ID NO:1.
35. The pharmaceutical composition for use according to item 34, wherein the GDNF polypeptide comprises amino acids 78-211 of SEQ ID NO:1.
36. The pharmaceutical composition for use according to any one of items 31 to 35, wherein the dose of recombinant GDNF polypeptide used corresponds to a dose of about 5 μg to about 20 μg in a mouse pup.
37. The pharmaceutical composition for use according to any one of items 31 to 36, wherein the pharmaceutically acceptable carrier is a saline solution or a gelling agent.
38. The pharmaceutical composition for use according to any one of items 31 to 37, wherein the pharmaceutical composition is for rectal administration through enema.
39. The pharmaceutical composition for use according to any one of items 31 to 38, wherein the pharmaceutical composition is for administration by injection into the distal colon wall.
40. The pharmaceutical composition for use according to any one of items 31 to 39, wherein the pharmaceutical composition is for administration once-a-day up to four times a day.
41. The pharmaceutical composition for use according to any one of items 31 to 40, wherein the pharmaceutical composition is for administration for at least 2 consecutive days.
42. The pharmaceutical composition for use according to any one of items 31 to 41, wherein the pharmaceutical composition is for use prior to surgical removal of the aganglionic or hypoganglionic segment in the subject.
43. The pharmaceutical composition for use according to any one of items 31 to 41, wherein the pharmaceutical composition is for use after surgical removal of the aganglionic or hypoganglionic segment in the subject.
44. The pharmaceutical composition for use according to item 42 or 43, wherein the surgical removal of the aganglionic or hypoganglionic segment is through pull-through surgery.
45. The pharmaceutical composition for use according to any one of items 31 to 44, wherein the enteric neuropathy is intestinal hypoganglionosis.
46. The pharmaceutical composition for use according to any one of items 31 to 44, wherein the enteric neuropathy is Hirschsprung disease (HSCR).
47. The pharmaceutical composition for use according to item 46, wherein the subject suffers from short-segment HSCR.
48. The pharmaceutical composition for use according to item 46 or 47, wherein the HSCR is sporadic HSCR.
49. The pharmaceutical composition for use according to any one of items 46 to 48, wherein the HSCR is associated with a reduced expression or activity of the RET receptor.
50. The pharmaceutical composition for use according to item 49, wherein the HSCR is associated with a mutation in the RET gene.
51. The pharmaceutical composition for use according to any one of items 31 to 50, wherein the enteric neurogenesis comprises production of enteric neurons and/or enteric glial cells.
52. The pharmaceutical composition for use according to item 51, wherein the enteric neurogenesis comprises production of enteric neurons and enteric glial cells.
53. The pharmaceutical composition for use according to item 51 or 52, wherein the production of enteric neurons and/or glial cells comprises proliferation of enteric neuron and/or enteric glia progenitors.
54. The pharmaceutical composition for use according to any one of items 31 to 53, wherein the pharmaceutical composition corrects the imbalance of nitrergic and cholinergic neuron subtypes located upstream of the aganglionic or hypoganglionic segment.
55. The pharmaceutical composition for use according to any one of items 31 to 54, wherein the pharmaceutical composition restores distal colon motility in the subject.
56. The pharmaceutical composition for use according to any one of items 31 to 55, wherein the pharmaceutical composition restores the proportions of lymphoid and/or myeloid immune cells in the distal colon of the subject.
57. The pharmaceutical composition for use according to any one of items 31 to 56, wherein the human subject is less than 5 years-old, or less than 1-year-old.
58. The pharmaceutical composition for use according to item 57, wherein the human subject is less than 6-month-old.
59. The pharmaceutical composition for use according to any one of items 31 to 58, wherein the pharmaceutical composition is for administration into the rectum and/or the sigmoid colon.
60. The pharmaceutical composition for use according to item 59, wherein the pharmaceutical composition is for administration into the rectosigmoid region.
61. Use of a pharmaceutical composition comprising a recombinant Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier for the manufacture of a medicament for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy, wherein the medicament is for administration into the distal colon of the subject.
62. The use according to item 61, wherein the GDNF polypeptide comprises an amino acid sequence having at least 70% identity with amino acids 78-211 of SEQ ID NO:1.
63. The use according to item 62, wherein the GDNF polypeptide comprises an amino acid sequence having at least 90% identity with amino acids 78-211 of SEQ ID NO:1.
64. The use according to item 63, wherein the GDNF polypeptide comprises an amino acid sequence having at least 95% identity with amino acids 78-211 of SEQ ID NO:1.
65. The use according to item 64, wherein the GDNF polypeptide comprises amino acids 78-211 of SEQ ID NO:1.
66. The use according to any one of items 61 to 65, wherein the dose of recombinant GDNF polypeptide used corresponds to a dose of about 5 μg to about 20 μg in a mouse pup.
67. The use according to any one of items 61 to 66, wherein the pharmaceutically acceptable carrier is a saline solution or a gelling agent.
68. The use according to any one of items 61 to 67, wherein the pharmaceutical composition is for rectal administration through enema.
69. The use according to any one of items 61 to 67, wherein the pharmaceutical composition is for administration by injection into the distal colon wall.
70. The use according to any one of items 61 to 69, wherein the pharmaceutical composition is for administration once-a-day up to four times a day.
71. The use according to any one of items 61 to 70, wherein the pharmaceutical composition is for administration for at least 2 consecutive days.
72. The use according to any one of items 61 to 71, wherein the pharmaceutical composition is used prior to surgical removal of the aganglionic or hypoganglionic segment in the subject.
73. The use according to any one of items 61 to 72, wherein the pharmaceutical composition is used after surgical removal of the aganglionic or hypoganglionic segment in the subject.
74. The use according to item 72 or 73, wherein the surgical removal of the aganglionic or hypoganglionic segment is through pull-through surgery.
75. The use according to any one of items 61 to 74, wherein the enteric neuropathy is intestinal hypoganglionosis.
76. The use according to any one of items 61 to 75, wherein the enteric neuropathy is Hirschsprung disease (HSCR).
77. The use according to item 76, wherein the subject suffers from short-segment HSCR.
78. The use according to item 76 or 77, wherein the HSCR is sporadic HSCR.
79. The use according to any one of items 76 to 78, wherein the HSCR is associated with a reduced expression or activity of the RET receptor.
80. The use according to item 79, wherein the HSCR is associated with a mutation in the RET gene.
81. The use according to any one of items 61 to 80, wherein the enteric neurogenesis comprises production of enteric neurons and/or enteric glial cells.
82. The use according to item 81, wherein the enteric neurogenesis comprises production of enteric neurons and enteric glial cells.
83. The use according to item 81 or 82, wherein the production of enteric neurons and/or glial cells comprises proliferation of enteric neuron and/or enteric glia progenitors.
84. The use according to any one of items 61 to 83, wherein the method corrects the imbalance of nitrergic and cholinergic neuron subtypes located upstream of the aganglionic or hypoganglionic segment.
85. The use according to any one of items 61 to 84, wherein the medicament restores distal colon motility in the subject.
86. The use according to any one of items 61 to 85, wherein the medicament restores the proportions of lymphoid and/or myeloid immune cells in the distal colon of the subject.
87. The use according to any one of items 61 to 86, wherein the human subject is less than 5 years-old, or less than 1-year-old.
88. The use according to item 87, wherein the human subject is less than 6-month-old.
89. The use according to any one of items 61 to 88, wherein the medicament is for administration into the rectum and/or the sigmoid colon.
90. The use according to item 89, wherein the medicament is for administration into the rectosigmoid region.
Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings.
In the Appended Drawings:
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the technology (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.
The terms “comprising”, “having”, “including”, and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to”) unless otherwise noted.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.
The use of any and all examples, or exemplary language (“e.g.”, “such as”) provided herein, is intended merely to better illustrate embodiments of the claimed technology and does not pose a limitation on the scope unless otherwise claimed.
No language in the specification should be construed as indicating any non-claimed element as essential to the practice of embodiments of the claimed technology.
Herein, the term “about” has its ordinary meaning. The term “about” is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10% of the recited values (or range of values).
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All subsets of values within the ranges are also incorporated into the specification as if they were individually recited herein.
Where features or aspects of the disclosure are described in terms of Markush groups or list of alternatives, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member, or subgroup of members, of the Markush group or list of alternatives.
Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in stem cell biology, cell culture, molecular genetics, immunology, immunohistochemistry, protein chemistry, and biochemistry).
Unless otherwise indicated, the recombinant protein, cell culture, and immunological techniques utilized in the present disclosure are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989), T. A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D. M. Glover and B. D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F. M. Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present), Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and J. E. Coligan et al. (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates until present).
In the studies described herein, the present inventors show that administration of a proper dosage of recombinant GDNF in the distal colon via rectal enema can induce permanent formation of new functioning enteric neurons and glia in otherwise aganglionic colon, and restoration of colon motility, in HSCR mouse models. Genetic lineage tracing show that SCPs located in extrinsic nerve fibers are one source for these newly generated enteric neurons and glia. It is further demonstrated that GDNF can stimulate neurogenesis in cultured explants of aganglionic colon from human HSCR patients. Thus, GDNF appeared as a primary candidate for postnatal reactivation of ENS progenitors in the aganglionic zone notably because of its ability to stimulate migration and proliferation of Schwann cells in a RET-independent but GFRα1-dependent manner through its alternative receptor neural cell adhesion molecule (NCAM). These results provide evidence that administration of recombinant GDNF administered in the colon (e.g., distal colon) may be used for the treatment for enteric neuropathies (e.g., ENS defects such as HSCR) i.e. for improving one or more of the pathological features of enteric neuropathies, in human patients.
Accordingly, in a first aspect, the present disclosure provides a method for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., Hirschsprung disease (HSCR) or intestinal hypoganglionosis), the method comprising administrating a pharmaceutical composition comprising an effective dose of a Glial cell line-Derived Neurotrophic Factor (GDNF) polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
The present disclosure also provides a method for restoring distal colon motility and/or epithelial barrier in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), the method comprising administrating a pharmaceutical composition comprising an effective dose of a GDNF polypeptide and a pharmaceutically acceptable carrier into the distal colon of the subject.
The present disclosure also provides the use of a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the composition is for administration into the distal colon of the subject.
The present disclosure also provides the use of a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for restoring distal colon motility in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the composition is for administration into the distal colon of the subject.
The present disclosure also provides the use of a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for the manufacture of a medicament for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the medicament is for administration into the distal colon of the subject.
The present disclosure also provides the use of a pharmaceutical composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier for the manufacture of a medicament for restoring distal colon motility in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), wherein the medicament is for administration into the distal colon of the subject.
The present disclosure also provides a pharmaceutical composition for inducing enteric neurogenesis in an aganglionic or hypoganglionic segment of the distal colon of a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), the composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition is for administration into the distal colon of the subject. The present disclosure also provides a pharmaceutical composition for restoring distal colon motility in a human subject suffering from an enteric neuropathy (e.g., HSCR or intestinal hypoganglionosis), the composition comprising a human GDNF polypeptide and a pharmaceutically acceptable carrier, and wherein the pharmaceutical composition is for administration into the distal colon of the subject.
The term “distal colon” as used herein refers to the last three portions of the colon, namely the descending colon, the sigmoid colon and the rectum. In an embodiment, the pharmaceutical composition is administered or is for administration into the rectum and/or the sigmoid colon. In an embodiment, the pharmaceutical composition is administered or is for administration into the rectosigmoid region, which comprises the last part of the sigmoid colon and the beginning of the rectum. The skilled person would understand that the pharmaceutical composition may be administered directly into the distal colon, or may be administered at a site away from the distal colon but using suitable means to provide delivery of the pharmaceutical composition (and more specifically of the human GDNF polypeptide) into the distal colon. For example, the pharmaceutical composition may comprise a coating that is specifically degraded under the conditions (e.g., pH, enzymatic environment, bacterial environment, etc.) of the distal colon, and thus pharmaceutical composition may be administered in another region of the gastrointestinal system but the human GDNF polypeptide will only be released once the pharmaceutical composition reaches the colon, and more specifically the distal colon. Approaches for colon specific drug delivery are well known in the art (see, e.g., Philip et al., Oman Med J. 2010 April; 25(2): 79-87; Lee et al., Pharmaceutics. 2020 January; 12(1): 68), and include pH-dependent systems (e.g., using pH-dependent polymers), receptor-mediated systems, magnetically-driven systems, delayed or time-dependent systems, microbially triggered drug delivery systems (e.g., comprising sugar-based polymers that may be degraded by enzymes produced by the colon microflora such as glucoronidase, xylosidase, arabinosidase, galactosidase), pressure controlled colonic delivery capsule (drug release induced by the higher pressures encountered in the colon), osmotic controlled drug delivery, as well as any combinations of these approaches (e.g., colon targeted delivery system (CODES™) using a combined approach of pH dependent and microbially triggered drug delivery).
The term “enteric neuropathy” as used herein refers to a disease associated with abnormalities in the ENS, including abnormal development of the ENS, e.g., abnormal number of neurons (hypoganglionosis, aganglionosis) and/or abnormal differentiation of neurons. Examples of enteric neuropathies include enteric dysganglionoses such as HSCR and intestinal hypoganglionosis. In an embodiment, the enteric neuropathy is HSCR. In another embodiment, the enteric neuropathy is intestinal hypoganglionosis.
The expression “inducing enteric neurogenesis” as used herein refers to an increase in the production of enteric neurons and/or enteric glial cells relative to prior to treatment with the composition comprising a human GDNF polypeptide. The enteric nervous system comprises various types of neurones including enteric primary afferent neurons (EPANs), excitatory circular muscle motorneurons, inhibitory circular muscle motorneurons, longitudinal muscle motorneurons, ascending interneurons, descending interneurons, secretomotor and vasomotor neurons, and intestinofugal neurons, as well as enteric glial cells (EGCs) that provide structural support to neurons and contribute to neuronal maintenance, survival, and function (Costa et al., Gut 2000(Suppl IV) 47: iv15-iv19; De Giorgio et al., American Journal of Physiology-Gastrointestinal and Liver Physiology, Vol. 303, No. 8: G887-G893, 2012).
The production of one or more of these cell types may be induced by the administration/use of the composition comprising a human GDNF polypeptide. In an embodiment, the production of EGCs, preferably Sox10-expressing EGCs, is induced by the administration/use of the composition comprising a human GDNF polypeptide. In an embodiment, the administration/use of the composition comprising a human GDNF polypeptide restores the enteric neurons/glial cell ratio in the colon (e.g., distal colon) of the patient. In a further embodiment, the enteric neurons/glial cell ratio in the colon (e.g., distal colon) of the patient is at least 0.5, e.g., between 0.5 and 1.5. In another embodiment, the administration/use of the composition comprising a human GDNF polypeptide restores the proportions of nitrergic (nNOS+) and cholinergic (ChAT+) neurons in the colon (e.g., distal colon) of the patient.
In another embodiment, the administration/use of the composition comprising a human GDNF polypeptide reduces the infiltration of inflammatory or immune cells (e.g., neutrophils) in the colon (e.g., distal colon). In another embodiment, the administration/use of the composition comprising a human GDNF polypeptide restores (partly or completely) the proportions of immune cells in the colon (e.g., distal colon).
The term “human GDNF polypeptide” as used herein refers to the native mature human GDNF protein, or to functional variants or fragments thereof that retain a biological activity of the native mature human GDNF protein, e.g., the ability to bind to a GDNF receptor (particularly the “rearranged during transfection” (RET) proto-oncogene and/or the Neural Cell Adhesion Molecule (NCAM) receptor) and trigger a signal in a cell expressing a GDNF receptor (e.g., RET and/or NCAM). The amino acid sequence of native human GDNF protein (isoform 1, the canonical sequence) is depicted in
In an embodiment, the human GDNF polypeptide is a recombinant human GDNF polypeptide. The term “recombinant” when made in reference to a protein or a polypeptide refers to a protein or polypeptide molecule that is not isolated from a natural source (e.g., biological sample), e.g., which is expressed from a recombinant nucleic acid construct created by means of molecular biological techniques. Referring to a nucleic acid construct as “recombinant” therefore indicates that the nucleic acid molecule has been manipulated using genetic engineering, i.e. by human intervention. Recombinant nucleic acid constructs may for example be introduced into a host cell by transformation (e.g., transduction or transfection).
Functional variants or fragments of native mature human GDNF protein may include one or more amino acid substitutions, deletions and/or additions relative to the native mature human GDNF protein, and may have a biological activity that is lower, equivalent or higher than that of the native mature human GDNF protein. In an embodiment, the functional variant or fragment has an activity that is equivalent (e.g., between 90% to 110%) or higher (e.g., more than 110%) to that of the native mature human GDNF protein. In an embodiment, the variant comprises one or more conservative substitutions. Conservative amino acid substitutions are known in the art, and include amino acid substitutions in which one amino acid having certain physical and or chemical properties is exchanged for another amino acid that has the same chemical or physical properties. For instance, the conservative amino acid substitution can be an acidic amino acid substituted for another acidic amino acid (e.g., Asp to Glu or vice-versa), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.). In another embodiment, the variants can comprise the amino acid sequence of the native GDNF protein or polypeptide with at least one non-conservative amino acid substitution. Preferably, the non-conservative amino acid substitution(s) enhance(s) the activity of the variant relative to that of the native mature human GDNF protein. In an embodiment, the human GDNF polypeptide has the ability to bind to the RET receptor. In an embodiment, the human GDNF polypeptide has the ability to bind to the NCAM receptor.
In an embodiment, the human GDNF polypeptide comprises at least 10, 15 or 20 amino acids (e.g., contiguous amino acids) from the mature human native GDNF protein. In an embodiment, the human GDNF polypeptide comprises the sequence ETTYDKILKNLSRNR (gliafin, SEQ ID NO:3), which corresponds to residues 153-167 of SEQ ID NO: 1 and is the putative binding domain of human GDNF to the NCAM receptor (see, Nielsen et al., J Neurosci. 2009 Sep. 9; 29(36): 11360-11376). In other embodiments, the human GDNF polypeptide comprises at least 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 amino acids (e.g., contiguous amino acids) from the mature human native GDNF protein.
In an embodiment, the human GDNF polypeptide comprises an amino acid sequence that is at least 50%, 60% or 70% identical to the sequence of residues 78-211 depicted in
Covalent modifications of the human GDNF polypeptide are included within the scope of this disclosure. For example, the native glycosylation pattern of the human GDNF polypeptide may be modified (Beck et al., Curr. Pharm. Biotechnol. 9: 482-501, 2008; Walsh, Drug Discov. Today 15: 773-780, 2010), and linking the human GDNF polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. The human GDNF polypeptide may comprise one or more modifications that confer additional biological properties to the polypeptide such as protease resistance, plasma protein binding, increased plasma half-life, tissue or intracellular penetration, etc. Such modifications include, for example, covalent attachment of molecules/moiety to the polypeptide such as fatty acids (e.g., C6-C18), attachment of proteins such as albumin (see, e.g., U.S. Pat. No. 7,268,113); sugars/polysaccharides (glycosylation), biotinylation or PEGylation (see, e.g., U.S. Pat. Nos. 7,256,258 and 6,528,485). The human GDNF polypeptide may also be conjugated to moieties to induce its multimerization or oligomerization (e.g., tetramerization), for example by fusing the human GDNF polypeptide to an oligomerization domain or to a molecule that may be oligomerized (e.g., biotin that may bind to 4 binding sites on streptavidin). The human GDNF polypeptide may also be conjugated to moieties that will target the GDNF polypeptide to the distal colon or to specific cells of the distal colon (e.g., Schwann cells and/or precursor thereof), for example using an antibody, antibody fragment or ligand that binds to a marker present on cells from the distal colon.
The human GDNF polypeptide can also be conjugated to one or more therapeutic or active agents (e.g., to a drug, or to another polypeptide to form a fusion polypeptide). Any method known in the art for conjugating the human GDNF polypeptide to another moiety (e.g., active agent) may be employed, including those methods described by Hunter et al. (1962) Nature, 144:945; David et al. (1974) Biochemistry, 13: 1014; Pain et al. (1981) J. Immunol. Meth., 40:219; Nygren, J. Histochem. and Cytochem., 30:407 (1982), and Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego.
In an embodiment, the effective dose of recombinant GDNF polypeptide administered or for administration to the human subject corresponds to a dose of about 5 μg to about 20 μg in a mouse pup, which is the range shown to be effective in the studies described herein. A 10 μl enema comprising a recombinant GDNF solution was administered to mouse pups. 10 μl is estimated to correspond to the volume necessary to fill the distal colon and rectum of the pups. Accordingly, administration of 5 μg GDNF in mice (pups) is achieved by administering 10 μl of a 0.5 μg/μl GDNF solution, and administration of 20 μg GDNF in mice (pups) is achieved by administering 10 μl of a 2.0 μg/μl GDNF solution. The volume required to fill the distal colon and rectum of a human baby may be estimated using the formula: 10 ml×weight of the baby (in kg). Accordingly, a dose of 5 μg GDNF in mice corresponds to about 5 mg per kg in a human baby, and a dose of 20 μg GDNF in mice corresponds to about 20 mg per kg in a human baby. Thus, in an embodiment, the effective dose of recombinant GDNF polypeptide administered or for administration to the human subject is about 5 mg to about 20 mg per kg, preferably about 10 mg to about 15 mg per kg. In an embodiment, the recombinant GDNF polypeptide is administered or is for administration through a 0.5 mg/ml to 2 mg/ml composition (solution or gel).
Formulations for rectal/distal colon administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the composition comprising GDNF. More recently, liquid suppositories have been developed. Liquid suppositories typically contain thermosensitive and/or mucoadhesive polymers such as poloxamers, Carbopol® (crosslinked polyacrylic acid polymers), sodium alginate, polycarbophil, hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose, and methylcellulose.
Formulations for rectal/distal colon administration may also be presented as an enema, a liquid-drug solution, suspension or emulsion that is injected into the rectum and the distal colon. The liquid in which the GDNF polypeptide is diluted may be water or a saline solution, for example.
Formulations for rectal/distal colon administration may also be in the form of a rectal foam or gel. Rectal gels are semi-solid formulations that contain a solvent trapped within a polymer network to create a viscous consistency. Viscosity of the gel can be modified by the addition of co-solvents (e.g., glycerin and propylene glycol) and electrolytes. Foams comprise a hydrophilic liquid continuous phase containing a foaming agent and a gaseous dispersion phase distributed throughout. Following rectal administration, they transition from a foam state to a liquid or semi-solid state on the mucosal surface. Foaming agents are typically amphiphilic substances that are important for foam generation and stabilization. The molecules contain hydrophilic components that are soluble in the aqueous phase and hydrophobic components that form micelles to minimize contact with the aqueous phase.
Administration into the rectum/distal colon may be performed using currently available endoscopes or specialized catheters designed for rectal administration or injection into the distal colon wall of medications and liquids, which may be placed safely and remain comfortably in the rectum for repeated use.
The composition comprising GDNF polypeptide may be administered according to any suitable dosage regimen, for example four times-a-day, twice-a-day, once-a-day, twice-a-week, once-a-week, etc. The treatment may be performed for any suitable period of time to achieve the desired effect, for example for 1 week, 2 weeks, 3 weeks or more.
In an embodiment, the above-mentioned treatment comprises the use/administration of more than one (i.e. a combination of) active/therapeutic agent, one of which being the above-mentioned pharmaceutical composition comprising a GDNF polypeptide. The combination of therapeutic agents and/or compositions may be administered or co-administered (e.g., consecutively, simultaneously, at different times) in any conventional dosage form. Coadministration in the context of the present disclosure refers to the use of more than one therapy in the course of a coordinated treatment to achieve an improved clinical outcome. The pharmaceutical composition comprising a GDNF polypeptide described herein may be used in combination with other therapies or drugs, for example analgesics or anti-inflammatory agents. The pharmaceutical composition comprising a GDNF polypeptide described herein may also be used in combination with an agent that stimulate ENS progenitor proliferation, such as a neurotrophic molecule.
In an embodiment, the above-mentioned treatment with a composition comprising GDNF polypeptide may be performed in combination with surgery (e.g., pull-through surgery of the Swenson, Soave or Duhamel type). Especially for neonates with HSCR, clinicians often recommend a trial of daily enema treatments prior to surgery. Addition of recombinant GDNF to the enema might increase the likelihood that children with HSCR responded well to pre-operative enema therapy. Accordingly, in an embodiment, the above-mentioned treatment with a composition comprising GDNF polypeptide is performed prior to pull-through surgery. Saline enemas are also commonly used in children with HSCR after pull-through surgery. Post-surgical problems in HSCR patients are believed to be due at least in part to hypoganglionosis in retained distal bowel, the so-called “transition zone”. Thus, addition of recombinant GDNF to the enema may be useful to correct the hypoganglionosis in retained distal bowel after surgery. Accordingly, in another embodiment, the above-mentioned treatment with a composition comprising GDNF polypeptide is performed after pull-through surgery.
In an embodiment, the above-mentioned treatment with a composition comprising GDNF polypeptide is performed in combination with ENS stem cell-based therapies, which are being considered for the treatment of HSCR. GDNF may be a useful adjunct to these therapies to promote engraftment.
HSCR is clinically subdivided into short-segment (S-HSCR) and long-segment forms (L-HSCR). S-HSCR, which occurs in >80% of cases, means the ENS is absent from rectum and sigmoid colon. L-HSCR means longer regions of distal bowel are aganglionic. The method/use described herein is for the treatment of a human patient suffering from S-HSCR or L-HSCR. In an embodiment, the method/use described herein is for the treatment of a human patient suffering from S-HSCR. In an embodiment, the method/use described herein is for the treatment of a human patient suffering from L-HSCR.
The HSCR patient may be an adult patient or pediatric patient. In an embodiment, the HSCR patient is a pediatric patient, preferably a patient that is less than 5, 4, 3 or 2 year-old, more preferably a patient that is less than 1 year-old or less than 6 month-old. In another embodiment, the patient is a male.
HSCR has been associated with mutations in RET, EDNRB, SOX10, PHOX2B, and ZFHX1B, as well as with Down syndrome or Trisomy 21 (Collagen VI-associated HSCR). There is also a significant sex difference with male to female ratio as high as 5 to 1. In an embodiment, the HSCR is Collagen VI-associated HSCR. In another embodiment, the HSCR is EDNRB mutation-associated HSCR. In an embodiment, the HSCR is male-biased HSCR. In an embodiment, the HSCR is a RET mutation-associated HSCR, e.g., HSCR associated with a mutation that reduces RET expression and/or activity in cells from the distal colon. The mutation may be a mutation in RET or in a protein involved in RET signaling. In an embodiment, the mutation is a mutation in the RET protein. Mutations in the RET gene on chromosome 10811.2 have been shown to account for 50% of familial and 15-20% of sporadic cases of HSCR, most of which (˜75%) were associated with L-HSCR.
In another embodiment, the HSCR is not a RET mutation-associated HSCR.
The present invention is illustrated in further details by the following non-limiting examples.
Mice. Holstein (Tg[Sox3-GFP,Tyr]HolNpin), TashT (Tg[SRY-YFP,Tyr]TashTNpin), and G4-RFP (Gata4p[5 kb]-RFP) lines were as previously described (all maintained on a FVB/N genetic background) (39, 40, 54), whereas Piebald-lethal (Ednrbs-l; JAX stock #000308; C3H/HeJ-057BL/6 mixed background) and Dhh-Cre (Tg[Dhh-cre]1Mejr; JAX stock #012929; FVB/N background) were obtained from The Jackson Laboratory. Other mouse lines used were R26(Floxed Stop)YFP (Gt[ROSA]26Sortm1(EYFP)Cos; provided by F. Costantini (Columbia University, USA) and maintained on an FVB/N background) (80).
For all enema treatments, mutant mouse pups were identified at P3 via pigmentation-based genotyping. Unless specified otherwise (see
For EdU incorporation assays, mouse pups received 10 μl intraperitoneal injections of a 10 mM EdU solution (ThermoFisher Scientific, Cat. # C10337) once a day during the 5-day (P4 to P8) GDNF enema treatment.
Tissue processing. All bowel tissues to be labelled were cut longitudinally along the mesentery, washed in PBS, pinned down on Sylgard-coated petri dishes, fixed with 4% PFA at 4° C. overnight, and finally microdissected to separate longitudinal/circular muscles (containing myenteric neural ganglia) from the submucosa/mucosa layer (containing submucosal neural ganglia). For experiments involving ex vivo analyses of living tissues, longitudinal/circular muscles and submucosa/mucosa layers were similarly microdissected, but without fixation. Instead this procedure was performed in ice-cold oxygenated Krebs solution (NaH2PO4-2H2O 0.187 g/L, NaCl 6.84 g/L, KCl 0.35 g/L, NaHCO32.10 g/L, Glucose 1.98 g/L, CaCl2)-2H2O 0.368 g/L, MgCl2-6H2O 0.244 g/L). For histological analyses, PFA-fixed bowel tissues were prepared as described above but without further microdissection, and fixed full-thickness bowel segments were then embedded in paraffin and transversally sectioned at 10 μm.
Tissue labelling and imaging. For immunofluorescence staining, whole microdissected tissues were permeabilized for 2 hours in blocking solution (10% FBS and 1% Triton™ X-100, in PBS) before being sequentially incubated with specific primary (at 4° C. overnight) and relevant secondary (at room temperature for 2 hours) antibodies, both diluted in blocking solution that was also used to wash tissues between all steps. All antibodies and dilution factors are listed in Table 1. EdU was detected using the Invitrogen Click-iT EdU Imaging Kit (ThermoFisher Scientific, Cat. # C10337) in accordance with the manufacturer's instructions. For histological analyses, cross-sections of full-thickness bowel tissues were stained with hematoxylin and eosin (H&E) as previously described (83).
All immunofluorescence images were acquired with either a 20X or a 60X objective on a confocal microscope (either Nikon A1R or Zeiss 710), except for H&E-stained sections that were imaged with a 10X objective using an Infinity-2 camera (Lumenera Corporation) mounted on a Leica DM 2000 microscope (Leica Microsystems Canada). Image analysis was performed with ImageJ, using the “multi-point” function for cell counting, and the “polygon selection” function for calculation of surface area.
In vivo and ex vivo analysis of colonic motility. In vivo analysis of distal colonic motility in P20 mice was performed using the bead latency test. Mice were anesthetized with 2% isoflurane and a 2 mm glass bead (Sigma, Cat. #1.04014) was inserted into the distal colon with a probe over a distance of 0.5 cm from the anus. Each mouse was then isolated in its cage without access to food and water, and monitored for the time required to expel the glass bead, which was taken as a proxy for distal colonic transit. The maximal time allowed to expel the bead was 30 minutes.
For ex vivo analysis of colonic motility, strips of living muscles from most distal colon (1 cm from the anus) of P20 mice were prepared as described above, and attached in the longitudinal direction in a Schuler organ bath (Harvard apparatus) filled with oxygenated Krebs solution. Muscle strips were initially stretched with a preload of 2 g of tension for 60 min, and contraction/relaxation of longitudinal muscles was then continuously recorded with a myograph (Narco Biosystems Inc., Model F-60) coupled to a computer equipped with the BIOPAC student Lab 4.0.2 software (BIOPAC Systems Inc.). Electrical field stimulation (EFS) was applied with a voltage stimulator (BIOPAC Systems Inc., Model BSL MP36/35) connected to electrodes, using parameters that activate enteric neurons without directly activating muscles (12 V, 20 Hz, 10 s train duration, and 300 μs stimulus pulse duration). This procedure was repeated 3 times, with 10 min washout periods between stimulations. To characterize the nitrergic and cholinergic components of EFS-induced contractile responses, N-nitro-L-arginine methyl ester (L-NAME; Sigma, Cat. # N5751) and atropine (Sigma, Cat. # A01132) were added to Krebs solution at a final concentration of 0.5 μM and 1 μM, respectively. The area under the curve (AUC) was measured during each EFS-induced response, and data were expressed in AUC (corresponding to the difference between the AUC measured 20 s after stimulation minus the AUC measured 20 s before stimulation).
Ex vivo analysis of paracellular permeability. Segments of living mucosa from most distal colon (1 cm from the anus) of P20 mice were prepared as described above, and mounted in Ussing chambers with 0.5 cm2 exposed surface area (Warner Instruments, Model U-9926). Each chamber contained 5 ml of DMEM/F12 medium (Wisent, Cat. #319-085-CL), which was maintained at 37° C. and continuously oxygenated (95% O2/5% CO2). After a 30 min equilibration period, 200 μl of apical medium was replaced with 200 μl of a 1 mg/ml solution of fluorescein isothiocyanate-conjugated dextran 4 kDa (FD4; Sigma, Cat. #60842-46-8). Fluorescence intensity of basolateral aliquots of 150 μl, reflecting paracellular transit from the luminal surface, was then measured every 30 min over a period of 3 hours, using a fluorimeter (TECAN, Model Infinite M1000). Fluorescence intensity was finally converted in amount of FD4 by comparison to a standard curve, and the average value for the 3-hour period was used to calculate paracellular permeability, which was expressed in ng of FD4 per surface of mucosa area per min (ng/cm2/min).
Microbiome analysis. Stool isolation, microbiome sequencing and data analysis were performed as previously described (38). Briefly, mice were sacrificed at P20 and their feces were directly collected from the colon (3 fecal pellets per mouse). Bacterial DNA was then extracted using the QIAamp® Fast DNA Stool Mini Kit (QIAGEN, Cat. #51604), and the V5-V6 region of the 16S rRNA gene was PCR amplified with a collection of previously described barcoded primers (84). Raw sequences generated with an Illumine MiSeq sequencer were paired and processed using the MOTHUR pipeline (85), and the BIOM package (86) was subsequently used to transfer biom files into R (87) for generating graphs of relative taxa abundance and beta diversity.
Western blot analysis. Organs from P8 or P20 mice were weighed and dissolved in RIPA buffer (25 mM Tris-HCL [pH7.6], 150 mM Sodium Chloride, 1% Nonidet P-40, 1% Sodium Deoxycholate, 0,1% Sodium Dodecyl Sulfate, containing 1X Roche Complete protease inhibitors), using 1 mL for every 100 mg of tissue. Samples were then sonicated on ice and centrifuged at 14,000 rpm for 15 minutes at 4° C., keeping the supernatants for western blot analysis. Equal volumes of samples were electrophoretically separated in an 18% sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and transferred to Immun-blot® PVDF membranes (Bio-Rad, Cat. #1620177). Membranes were subsequently incubated in blocking solution (5% skimmed milk and 0.1% Tween® 20, in TBS), followed by incubation with either mouse anti-GDNF (Santa Cruz Biotechnology, Cat. # sc-13147; 1:500 dilution factor) or rabbit anti-αTubulin (Abcam, Cat. # ab176560; 1:70,000 dilution factor) primary antibodies, and then relevant horseradish peroxidase-conjugated secondary antibodies, all diluted in blocking solution. Each incubation was for 60 min at room temperature, each time interspersed by 3 washes with blocking solution. Proteins were finally visualized using Immobilon western chemiluminescent HRP substrate (Millipore Sigma, Cat. # WBKLS0050) and Fusion FX imaging system (Vilber).
Ex vivo time-lapse imaging and culture of murine aganglionic colon tissues. For time-lapse imaging, strips of living muscles from the last cm of distal colon from P4 HolTg/Tg; G4-RFP double transgenic pups were prepared as described above, and pinned down in Sylgard-coated 35 mm ibidi μ-dishes (ibidi, Cat. #81156). Muscle strips were cultured in suspension in DMEM/F12 medium (Wisent, Cat. #319-085-CL) supplemented with 10% FBS and 1001 U/ml antibiotic-antimycotic with or without 5 μg/ml GDNF under standard culture conditions (37° C., 5% CO2). After 72 h of culture, each petri dish was placed in a microscope incubation chamber (Okolab) for 10 hours under the same culture conditions, and image stacks (250 μm-thick) of RFP-labelled extrinsic nerves and SCPs were acquired every 10 min, using a 20X objective on a Nikon A1R confocal unit as previously described (39).
For ex vivo induction of neurogenesis, strips of living muscles from the last cm of distal colon from P4 HolTg/Tg pups were prepared and cultured as described above, with the notable exceptions that culture was performed in presence of 0.5 μM EdU and for a more extended period of time. After 96 h of culture, tissues were fixed with PFA and processed for immunofluorescence and EdU labelling.
Culture of human aganglionic colon tissues. Human samples of sigmoid colon were obtained from 12 HSCR patients undergoing Swenson-type surgical resection of the aganglionic zone, as confirmed by histopathological analysis. Nine patients (7 boys and 2 girls; aged between 28 and 1638 days at the time of surgery) were recruited at the Centre Hospitalier Universitaire Sainte-Justine (Montreal, Canada) while 3 patients were recruited at the Children's Hospital of Philadelphia (2 boys and 1 girl; aged between 300 and 1177 days at the time of surgery). After the surgery, full-thickness colon tissues were placed in ice-cold Krebs solution or Belter UW Cold Storage Solution (Bridge to Life Ltd.) and immediately brought to the relevant research laboratory. Strips of living muscles were then prepared as described above and cut in smaller pieces of 0.5 cm×0.5 cm. At least one of these small pieces was immediately fixed and kept aside for validation of aganglionosis via immunofluorescence, while the others were cultured for 96 h as described above for inducing neurogenesis in mouse tissues. Samples from two patients (aged of 86 and 1638 days at the time of surgery) were in addition cultured for 7 days, under the same conditions. At the end of culture period, all tissues were fixed with PFA and processed for immunofluorescence and EdU labelling.
Profiling of immune cell populations in P20 colon. Holstein mice were treated or not with GDNF by enemas (daily administration of 10 μg of GDNF (10 μl at 1 μg/μl) for 5 consecutive days between P4 to P8. At P20, the colon of GDNF-treated Holstein and control (untreated Holstein and WT) mice was microdissected, cleaned in cold RPMI medium to remove stool, cut into small pieces, mechanically dissociated, and filtrated (40 μm). Dissociated cells were then recovered by centrifugation, resuspended in 1 ml of ice-cold RPMI with 2% FBS, and counted with a hemocytometer. For every experimental and control groups, 1×106 dissociated cells were incubated for 1 h on ice with a cocktail of 14 fluorescently labeled antibodies specific for either lymphoid or myeloid cell populations. Quantitative profiling was subsequently performed using an LSR Fortessa cytometer (BD Biosciences) and FlowJo software (FlowJo LLC).
Statistics. All experiments were performed with a minimum of three biological replicates. Where relevant, the exact number of independent replicates (n) and statistical tests used to calculate P values are included in figures and/or legends. P values were determined using GraphPad Prism 6, with the exception of microbiome data that were analyzed with R software (The R Foundation for Statistical Computing, Vienna, Austria).
It was first tested if GDNF enemas in young mice could enhance enteric neuron numbers and restore function in distal aganglionic bowel using three mouse models of short-segment HSCR. Selected lines were Holstein (HolTg/Tg; a model for Trisomy 21 [Collagen VI]-associated HSCR) (39), TashT (TashTTg/Tg; a model for male-biased HSCR) (40), and Piebald-lethal (EdnrbS-l/s-l; a model for EDNRB mutation-associated HSCR) (41). The enema volume necessary to fill whole colon, concentration of GDNF homodimer (30 kDa), treatment time window, as well as duration and frequency of therapy were first determined with HolTg/Tg pups (
Variability in response to GDNF enemas was observed in mutant mouse lines that are clearly GDNF responsive (
To determine how GDNF enemas enhanced survival of HSCR mouse models, the hypothesis that enhanced survival was caused by postnatal enteric neurogenesis in distal colon aganglionic was tested. P20 animals were analyzed because HolTg/Tg mice generally reach this stage even without enema treatment (
Importantly, EdU labeling confirmed that GDNF induced proliferation of neuron and glia progenitors during the 5-day treatment from P4 to P8. Immunofluorescent staining of P20 HolTg/Tg colon from mice that received daily EdU injections during the GDNF treatment period revealed many EdU+ HuC/D+ (presumptive neurons) and EdU+ SOX10+ (presumptive glia or neuron/glia progenitors) in both myenteric and submucosal ganglia (
Focusing on the HolTg/Tg model, it was next determined to what extent GDNF-induced ENS in the distal colon resembles WT at P20. Average neuron-to-glia ratio within GDNF-induced myenteric ganglia (0.77±0.09 neurons/glia) was statistically similar to WT (0.96±0.06 neurons/glia, P=0.16) (
To evaluate function of P20 GDNF-induced myenteric ganglia, colonic motility was analyzed in vivo using the bead latency test. Control HolTg/Tg mice did not expel a glass bead inserted into their rectum during the 30-minute observation period, but a subset of GDNF-treated HolTg/Tg did expel the bead in 10-21 min, a bit slower than WT mice (range of 2-8 min) (
To complement ENS analyses, other HSCR-associated bowel anomalies were evaluated. HolTg/Tg mouse colon had thicker smooth muscles and more neutrophils than WT mice, but GDNF-treated HolTg/Tg mouse colon was similar to WT (
To elucidate how GDNF induces enteric neurogenesis, GDNF distribution in bowel was first evaluated via Western blot, taking advantage of size differences between recombinant (15 kDa) and endogenous (20 kDa, glycosylated) GDNF proteins in SDS-PAGE gels. Consistent with increased epithelial permeability in distal colon of HolTg/Tg mice (
It was next assessed whether nerve-associated Schwann cells could be GDNF-targeted ENS progenitors. To test this hypothesis, response of Schwann cells in extrinsic nerve fibers to GDNF was first assessed, using live explants of distal colon muscularis externa from P4 HolTg/Tg; G4-RFP double transgenic pups. In these mice, neural crest derivatives including SCPs are marked by RFP fluorescence (54). Time-lapse imaging of explants after 72 h of culture in presence or absence of GDNF (5 μg/ml) suggested GDNF stimulates both migration and proliferation of SCPs along extrinsic nerves (
To further demonstrate SCPs are a source of GDNF-induced neurons and glia, in vivo genetic cell lineage tracing with the Schwann lineage-specific Cre driver transgene Dhh-Cre and the Rosa26 Cre reporter allele R26(Floxed Stop)YFP in the Holstein [FVB/N] mutant background was used. Intriguingly, untreated Dhh-CreTg/+; R26YFP/+ and HolTg/Tg; Dhh-CreTg/+; R26YFP/+ animals had a lower than expected number of YFP+ SCP-derived neurons and glia in proximal and mid colon. While SCPs were previously reported to contribute 20% of colonic neurons in a mixed C57BL/6-129Sv genetic background at 1 month of age (29), they were found to contribute only 5-7% of myenteric neurons in a pure FVB/N genetic background at P20, and this contribution increased to 10-11% in the presence of the homozygous Holstein mutation (
To test if GDNF could induce new enteric neurons in human tissue, an ex vivo model was needed. It was discovered that 96 hrs of GDNF treatment ex vivo induced neurons in all HolTg/Tg distal colon aganglionic tissues, but neurogenesis was much less efficient than in vivo. Only 3 to 67 neurons were seen in these 1 cm-long explants (
Finally, it was tested if GDNF could induce neurogenesis in aganglionic human colon muscle from children who had Swenson pull-through surgery to resect aganglionic distal bowel. The cohort consisted of 12 children. Epidemiologic characteristics were typical of HSCR (i.e., mostly sporadic, male-biased, short-segment) (Table 2). Patients who underwent Soave surgery were not enrolled because muscularis externa is not resected from the most distal colon with this approach. For each subject, full-thickness resected aganglionic colon was collected on the day of surgery and immediately micro-dissected to remove mucosal and submucosal layers. Remaining muscularis externa was cut into smaller pieces and cultured with or without GDNF. Exposure to GDNF for 96 h markedly increased the proportion of EdU+ SCPs in 9/9 human tissues where EdU was added to media (
Multi-color flow cytometry analysis shows that the abnormal proportions of immune cells observed in the colon of untreated HolTg/Tg mice become generally normalized back to WT immune cell proportions upon GDNF treatment. For a majority of markers, density plots shows either a complete (B cells, CD73+ T cells, CD44+CD62L+ T cells, RORy+ T cells, CX3CR1+MHC-II+ macrophages) or at least partial (CD4+ T cells, CD39+ T cells, CD25+ T cells, Ly-6C+CD64+ monocytes, F4-80+MHC-II+ macrophages, CD11b+CD103− macrophages) rescue. The results are summarized in Table 3.
Although the present invention has been described hereinabove by way of specific embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention as defined in the appended claims. In the claims, the word “comprising” is used as an open-ended term, substantially equivalent to the phrase “including, but not limited to”. The singular forms “a”, “an” and “the” include corresponding plural references unless the context clearly dictates otherwise.
The present application claims the benefit of U.S. provisional application Ser. No. 62/950,781, filed on Dec. 19, 2019, which is incorporated herein by reference.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CA2020/051746 | 12/18/2020 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 62950781 | Dec 2019 | US |
